UroGen Pharma Ltd.
Stock Forecast, Prediction & Price Target
UroGen Pharma Ltd. (URGN) stock Price Target by analysts
$25
Potential upside: 31.92%
UroGen Pharma Ltd. price prediction
What is UroGen Pharma Ltd. stock analysts` prediction?
UroGen Pharma Ltd. stock forecast: Based on 1 Wall Street analysts` predicted price targets for UroGen Pharma Ltd. in the last 3 months, the avarage price target is $25, with a high forecast of $NaN. The average price target represents a 31.92% change from the last price of $18.95.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
UroGen Pharma Ltd. stock Price Target by analysts
Full breakdown of analysts given UroGen Pharma Ltd. price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Jason Kolbert EF Hutton | 0% 0/1 | 11 months ago | $25 31.92% upside | $12.6 | StreetInsider | Previous targets (0) |
Paul Choi Goldman Sachs | 0% 0/1 | about 1 year ago | $22 16.09% upside | $17.5 | StreetInsider | Previous targets (0) |
Leland Gershell Oppenheimer | 0% 0/3 | about 1 year ago | $40 111.08% upside | $17.5 | TheFly | Previous targets (2) |
Stephen Richardson Evercore ISI | 0% 0/1 | about 1 year ago | $46 142.74% upside | $20.26 | Benzinga | Previous targets (0) |
Raghuram Selvaraju H.C. Wainwright | 0% 0/1 | about 1 year ago | $60 216.62% upside | $17.5 | TheFly | Previous targets (0) |
Leland Gershell Oppenheimer | 0% 0/3 | over 1 year ago | $32 68.86% upside | $13.07 | StreetInsider | Previous targets (2) |
Leland Gershell Oppenheimer | 0% 0/3 | over 1 year ago | $34 79.41% upside | $14.46 | StreetInsider | Previous targets (2) |
Unknown H.C. Wainwright | N/A | over 2 years ago | $23 21.37% upside | $7.94 | Benzinga | N/A |
UroGen Pharma Ltd. Financial Estimates
UroGen Pharma Ltd. Revenue Estimates
UroGen Pharma Ltd. EBITDA Estimates
UroGen Pharma Ltd. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $48.04M N/A | $64.35M 33.95% | $82.71M 28.52% | Avg: $151.56M Low: $133.32M High: $169.79M avg. 83.23% | Avg: $253.89M Low: $228.45M High: $273.43M avg. 67.52% | Avg: $398.25M Low: $358.34M High: $428.89M avg. 56.85% | Avg: $522.6M Low: $470.24M High: $562.81M avg. 31.22% |
Net Income
% change YoY
| $-110.82M N/A | $-109.16M 1.49% | $-102.24M 6.33% | Avg: $-97.11M Low: $-90.25M High: $-46.42M avg. 5.01% | Avg: $-30M Low: $-40.36M High: $-6.34M avg. 69.11% | Avg: $61.70M Low: $53.66M High: $67.87M avg. 305.68% | Avg: $122.54M Low: $106.58M High: $134.80M avg. 98.59% |
EBITDA
% change YoY
| $-75.00M N/A | $-78.03M -4.03% | $-63.83M 18.19% | Avg: $-144.64M Low: $-162.04M High: $-127.23M avg. -126.60% | Avg: $-242.30M Low: $-260.95M High: $-218.02M avg. -67.52% | Avg: $-380.06M Low: $-409.31M High: $-341.98M avg. -56.85% | Avg: $-498.73M Low: $-537.12M High: $-448.77M avg. -31.22% |
EPS
% change YoY
| -$4.96 N/A | -$4.79 3.42% | -$3.55 25.88% | Avg: -$2.53 Low: -$3.13 High: -$1.61 avg. 28.73% | Avg: -$0.81 Low: -$1.4 High: -$0.22 avg. 67.98% | Avg: $2.14 Low: $1.86 High: $2.35 avg. 364.19% | Avg: $4.25 Low: $3.7 High: $4.68 avg. 98.59% |
Operating Expenses
% change YoY
| $135.17M N/A | $135.74M 0.41% | $138.88M 2.31% | Avg: $101.73B Low: $89.49B High: $113.97B avg. 73150.57% | Avg: $170.42B Low: $153.35B High: $183.54B avg. 67.52% | Avg: $267.32B Low: $240.54B High: $287.89B avg. 56.85% | Avg: $350.79B Low: $315.65B High: $377.79B avg. 31.22% |
FAQ
What is UroGen Pharma Ltd. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 119.60% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -90.25M, average is -97.11M and high is -46.42M.
What is UroGen Pharma Ltd. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 59.70% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $133.32M, average is $151.56M and high is $169.79M.
What is UroGen Pharma Ltd. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 139.87% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$3.13, average is -$2.53 and high is $-1.61.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering UroGen Pharma Ltd. stock. The most successful analyst is Jason Kolbert.